Rep. Robert Bresnahan, Jr. Buys DexCom, Inc. (NASDAQ:DXCM) Stock

Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently bought shares of DexCom, Inc. NASDAQ: DXCM. In a filing disclosed on June 09th, the Representative disclosed that they had bought between $1,001 and $15,000 in DexCom stock on May 15th. The trade occurred in the Representative's "JP MORGAN BROKERAGE ACCOUNT" account.

Representative Robert Bresnahan, Jr. also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Zoom Communications NASDAQ: ZM on 6/25/2025.
• Purchased $1,001 - $15,000 in shares of Coinbase Global NASDAQ: COIN on 6/24/2025.
• Purchased $1,001 - $15,000 in shares of Circle Internet Group NYSE: CRCL on 6/24/2025.
• Sold $1,001 - $15,000 in shares of Amazon.com NASDAQ: AMZN on 6/23/2025.
• Sold $1,001 - $15,000 in shares of Chubb NYSE: CB on 6/13/2025.
• Sold $1,001 - $15,000 in shares of Atlassian NASDAQ: TEAM on 6/11/2025.
• Purchased $1,001 - $15,000 in shares of ServiceTitan NASDAQ: TTAN on 6/11/2025.
• Sold $1,001 - $15,000 in shares of Datadog NASDAQ: DDOG on 6/11/2025.
• Sold $1,001 - $15,000 in shares of GitLab NASDAQ: GTLB on 6/11/2025.
• Purchased $1,001 - $15,000 in shares of Broadcom NASDAQ: AVGO on 6/11/2025.

DexCom Stock Performance

Shares of NASDAQ DXCM traded up $2.25 during trading on Friday, reaching $88.99. 3,072,147 shares of the company traded hands, compared to its average volume of 2,733,721. The firm has a 50 day simple moving average of $84.58 and a 200-day simple moving average of $80.41. The company has a quick ratio of 1.32, a current ratio of 1.50 and a debt-to-equity ratio of 0.55. The stock has a market capitalization of $34.89 billion, a PE ratio of 66.41, a P/E/G ratio of 1.85 and a beta of 1.44. DexCom, Inc. has a 52-week low of $57.52 and a 52-week high of $93.25.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). The company had revenue of $1.04 billion for the quarter, compared to analysts' expectations of $1.02 billion. DexCom had a net margin of 12.90% and a return on equity of 30.05%. The business's revenue was up 12.5% compared to the same quarter last year. During the same period in the previous year, the business earned $0.32 EPS. Equities research analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current year.

Institutional Investors Weigh In On DexCom

Several large investors have recently bought and sold shares of DXCM. Private Trust Co. NA increased its position in DexCom by 266.3% in the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock worth $26,000 after purchasing an additional 245 shares during the last quarter. Golden State Wealth Management LLC increased its position in DexCom by 211.2% in the first quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock worth $27,000 after purchasing an additional 264 shares during the last quarter. Zions Bancorporation National Association UT bought a new stake in DexCom in the first quarter worth $27,000. Optiver Holding B.V. bought a new stake in DexCom in the fourth quarter worth $33,000. Finally, TD Private Client Wealth LLC boosted its stake in DexCom by 62.8% during the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock worth $34,000 after buying an additional 167 shares during the period. Institutional investors own 97.75% of the company's stock.

Analyst Ratings Changes

A number of research firms recently issued reports on DXCM. The Goldman Sachs Group began coverage on shares of DexCom in a report on Friday, May 30th. They issued a "buy" rating and a $104.00 price objective on the stock. Barclays raised their price objective on shares of DexCom from $90.00 to $93.00 and gave the stock an "equal weight" rating in a report on Monday, May 5th. Truist Financial began coverage on shares of DexCom in a report on Monday, June 16th. They issued a "buy" rating and a $102.00 price objective on the stock. Citigroup reissued a "buy" rating and issued a $102.00 price objective (up previously from $82.00) on shares of DexCom in a report on Thursday, May 22nd. Finally, Canaccord Genuity Group lifted their price target on shares of DexCom from $103.00 to $106.00 and gave the company a "buy" rating in a report on Friday, May 2nd. Four investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, DexCom has an average rating of "Moderate Buy" and a consensus target price of $99.60.

Insider Activity

In other DexCom news, Director Mark G. Foletta sold 2,750 shares of DexCom stock in a transaction on Monday, June 16th. The shares were sold at an average price of $83.13, for a total transaction of $228,607.50. Following the completion of the transaction, the director directly owned 56,621 shares of the company's stock, valued at $4,706,903.73. The trade was a 4.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Sadie Stern sold 6,184 shares of DexCom stock in a transaction on Tuesday, May 27th. The stock was sold at an average price of $85.11, for a total transaction of $526,320.24. Following the transaction, the executive vice president directly owned 109,621 shares of the company's stock, valued at $9,329,843.31. The trade was a 5.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 27,190 shares of company stock valued at $2,281,732 over the last ninety days. 0.32% of the stock is owned by corporate insiders.

About Representative Bresnahan

Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania's 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania's 8th Congressional District. He declared candidacy for the 2026 election. Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.